Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2008-2014

FUNDING AMOUNT

732057 USD

ABSTRACT

Angiogenesis, necessary for tumor growtti involves cell proliferation and directed migration. Ttius, there is clearly a crucial role of cytoskeletal microtubule (MT) dynamics in angiogenesis; linking perturbations of MT dynamics to Inhibition of tumor angiogeneisis. Our preliminary data strongly suggest that a semisynthetic tubulin-binding anticancer agent,(S)-3-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]-dioxolo[4,5- g]-iso-quinolin-5-yl)-6,7-dimethoxylsobenzofuran-1(3H)-one (EM011), has potent antiangiogenic activity (based upon NCI-DTP antiangiogenic drug screen). Our hypothesis is that EM011 will sen/e as an effective anticancer agent since it can target the MT cytoskeleton without causing any gross effects (over- or depolymerization of MTs) with concomitant antiangiogenic effects. The specific aims for the mentored phase were: Aim 1. Evaluation of the antiangiogenic efficacy of EM011. Aim 2. Determination of EM011's effect on the dynamic instability of MTs, HIF-lalpha expression and transactivation of downstream targets such as VEGF. We have successfully accomplished the proposed research in the K99 phase. Based upon the nontoxic attributes of EM011, we rationalize that combination of EM011 with other angiogenic inhibitors that function through independent mechanisms but show toxicity at their maximum tolerated doses (MTDs), presents a unique opportunity to reduce their doses to maximize therapeutic outcomes with decreased toxicity. The ROO phase of the project will focus on 2 aims: Aim 3. Investigation of potential synergistic antiproliferative and antiangiogenic effects of combinations of EM011 and ZD6474 (a tyrosine kinase inhibitor), or thalidomide (endothelial cell proliferation inhibitor) in breast (MDA-MB-231) and prostate (PC-3) cancer cells. Aim 4. Determination of the In vivo efficacy of EM011 and its synergistic combinations with ZD6474 or thalidomide, as inhibitors of experimental primary and metastatic breast and prostate cancers in real-time using non-invasive bioluminescent imaging. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=8321603

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "732057"
    }, 
    "description": "Angiogenesis, necessary for tumor growtti involves cell proliferation and directed migration. Ttius, there is clearly a crucial role of cytoskeletal microtubule (MT) dynamics in angiogenesis; linking perturbations of MT dynamics to Inhibition of tumor angiogeneisis. Our preliminary data strongly suggest that a semisynthetic tubulin-binding anticancer agent,(S)-3-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]-dioxolo[4,5- g]-iso-quinolin-5-yl)-6,7-dimethoxylsobenzofuran-1(3H)-one (EM011), has potent antiangiogenic activity (based upon NCI-DTP antiangiogenic drug screen). Our hypothesis is that EM011 will sen/e as an effective anticancer agent since it can target the MT cytoskeleton without causing any gross effects (over- or depolymerization of MTs) with concomitant antiangiogenic effects. The specific aims for the mentored phase were: Aim 1. Evaluation of the antiangiogenic efficacy of EM011. Aim 2. Determination of EM011's effect on the dynamic instability of MTs, HIF-lalpha expression and transactivation of downstream targets such as VEGF. We have successfully accomplished the proposed research in the K99 phase. Based upon the nontoxic attributes of EM011, we rationalize that combination of EM011 with other angiogenic inhibitors that function through independent mechanisms but show toxicity at their maximum tolerated doses (MTDs), presents a unique opportunity to reduce their doses to maximize therapeutic outcomes with decreased toxicity. The ROO phase of the project will focus on 2 aims: Aim 3. Investigation of potential synergistic antiproliferative and antiangiogenic effects of combinations of EM011 and ZD6474 (a tyrosine kinase inhibitor), or thalidomide (endothelial cell proliferation inhibitor) in breast (MDA-MB-231) and prostate (PC-3) cancer cells. Aim 4. Determination of the In vivo efficacy of EM011 and its synergistic combinations with ZD6474 or thalidomide, as inhibitors of experimental primary and metastatic breast and prostate cancers in real-time using non-invasive bioluminescent imaging.", 
    "endDate": "2014-08-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.48336.3a", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2441509", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2441509"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R00CA131489"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "therapeutic outcome", 
      "cytoskeletal microtubules", 
      "prostate", 
      "semisynthetic tubulin", 
      "endothelial cell proliferation inhibitor", 
      "independent mechanisms", 
      "thalidomide", 
      "inhibitors", 
      "antiangiogenic efficacy", 
      "angiogenesis", 
      "tumor growtti", 
      "nontoxic attributes", 
      "MTDs", 
      "preliminary data", 
      "prostate cancer", 
      "decreased toxicity", 
      "g]-iso-quinolin-5-yl)-6,7-dimethoxylsobenzofuran-1(3H)-one", 
      "Aim 1", 
      "migration", 
      "potent antiangiogenic activity", 
      "agents", 
      "crucial role", 
      "unique opportunity", 
      "downstream targets", 
      "NCI-DTP antiangiogenic drug screen", 
      "dynamic instability", 
      "ZD6474", 
      "gross effects", 
      "metastatic breast", 
      "cell proliferation", 
      "novel tubulin", 
      "EM011", 
      "EM011's effect", 
      "antiangiogenic effects", 
      "doses", 
      "Aim 4", 
      "antiangiogenic role", 
      "investigation", 
      "concomitant antiangiogenic effects", 
      "other angiogenic inhibitors", 
      "synergistic combination", 
      "project", 
      "anticancer", 
      "MT cytoskeleton", 
      "maximum", 
      "MT dynamics", 
      "dynamics", 
      "HIF-lalpha expression", 
      "aim", 
      "depolymerization", 
      "Ttius", 
      "transactivation", 
      "ROO phase", 
      "mentored phase", 
      "cancer cells", 
      "MDA-MB-231", 
      "toxicity", 
      "specific aim", 
      "VEGF", 
      "non-invasive bioluminescent imaging", 
      "experimental primary", 
      "perturbations", 
      "In Vivo Efficacy", 
      "evaluation", 
      "Aim 2", 
      "inhibition", 
      "hypothesis", 
      "tyrosine kinase inhibitors", 
      "determination", 
      "K99 phase", 
      "effective anticancer agents", 
      "combination", 
      "research", 
      "tumor angiogeneisis", 
      "breast", 
      "potential synergistic antiproliferative", 
      "PC-3"
    ], 
    "name": "Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.256304.6", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.256304.6", 
          "name": "GEORGIA STATE UNIVERSITY", 
          "type": "Organization"
        }, 
        "familyName": "ANEJA", 
        "givenName": "RITU", 
        "id": "sg:person.01365356361.20", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.01365356361.20", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2441509"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2021-01-20T03:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_5.xml.gz", 
    "startDate": "2008-09-12T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=8321603"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2441509'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2441509'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2441509'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2441509'


 

This table displays all metadata directly associated to this object as RDF triples.

121 TRIPLES      19 PREDICATES      99 URIs      91 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2441509 schema:about anzsrc-for:2211
2 schema:amount N4d0199b58a1e4a20b476707b7790d0d7
3 schema:description Angiogenesis, necessary for tumor growtti involves cell proliferation and directed migration. Ttius, there is clearly a crucial role of cytoskeletal microtubule (MT) dynamics in angiogenesis; linking perturbations of MT dynamics to Inhibition of tumor angiogeneisis. Our preliminary data strongly suggest that a semisynthetic tubulin-binding anticancer agent,(S)-3-((R)-9-bromo-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]-dioxolo[4,5- g]-iso-quinolin-5-yl)-6,7-dimethoxylsobenzofuran-1(3H)-one (EM011), has potent antiangiogenic activity (based upon NCI-DTP antiangiogenic drug screen). Our hypothesis is that EM011 will sen/e as an effective anticancer agent since it can target the MT cytoskeleton without causing any gross effects (over- or depolymerization of MTs) with concomitant antiangiogenic effects. The specific aims for the mentored phase were: Aim 1. Evaluation of the antiangiogenic efficacy of EM011. Aim 2. Determination of EM011's effect on the dynamic instability of MTs, HIF-lalpha expression and transactivation of downstream targets such as VEGF. We have successfully accomplished the proposed research in the K99 phase. Based upon the nontoxic attributes of EM011, we rationalize that combination of EM011 with other angiogenic inhibitors that function through independent mechanisms but show toxicity at their maximum tolerated doses (MTDs), presents a unique opportunity to reduce their doses to maximize therapeutic outcomes with decreased toxicity. The ROO phase of the project will focus on 2 aims: Aim 3. Investigation of potential synergistic antiproliferative and antiangiogenic effects of combinations of EM011 and ZD6474 (a tyrosine kinase inhibitor), or thalidomide (endothelial cell proliferation inhibitor) in breast (MDA-MB-231) and prostate (PC-3) cancer cells. Aim 4. Determination of the In vivo efficacy of EM011 and its synergistic combinations with ZD6474 or thalidomide, as inhibitors of experimental primary and metastatic breast and prostate cancers in real-time using non-invasive bioluminescent imaging.
4 schema:endDate 2014-08-31T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
6 schema:identifier N1b7db55a599a43019fda66c37cf9d9b6
7 Nb8061ef097fa4809a8bdfa5c9145daf5
8 schema:inLanguage en
9 schema:keywords Aim 1
10 Aim 2
11 Aim 4
12 EM011
13 EM011's effect
14 HIF-lalpha expression
15 In Vivo Efficacy
16 K99 phase
17 MDA-MB-231
18 MT cytoskeleton
19 MT dynamics
20 MTDs
21 NCI-DTP antiangiogenic drug screen
22 PC-3
23 ROO phase
24 Ttius
25 VEGF
26 ZD6474
27 agents
28 aim
29 angiogenesis
30 antiangiogenic effects
31 antiangiogenic efficacy
32 antiangiogenic role
33 anticancer
34 breast
35 cancer cells
36 cell proliferation
37 combination
38 concomitant antiangiogenic effects
39 crucial role
40 cytoskeletal microtubules
41 decreased toxicity
42 depolymerization
43 determination
44 doses
45 downstream targets
46 dynamic instability
47 dynamics
48 effective anticancer agents
49 endothelial cell proliferation inhibitor
50 evaluation
51 experimental primary
52 g]-iso-quinolin-5-yl)-6,7-dimethoxylsobenzofuran-1(3H)-one
53 gross effects
54 hypothesis
55 independent mechanisms
56 inhibition
57 inhibitors
58 investigation
59 maximum
60 mentored phase
61 metastatic breast
62 migration
63 non-invasive bioluminescent imaging
64 nontoxic attributes
65 novel tubulin
66 other angiogenic inhibitors
67 perturbations
68 potent antiangiogenic activity
69 potential synergistic antiproliferative
70 preliminary data
71 project
72 prostate
73 prostate cancer
74 research
75 semisynthetic tubulin
76 specific aim
77 synergistic combination
78 thalidomide
79 therapeutic outcome
80 toxicity
81 transactivation
82 tumor angiogeneisis
83 tumor growtti
84 tyrosine kinase inhibitors
85 unique opportunity
86 schema:name Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent
87 schema:recipient N2c33ecbb833b4ef6ab09e10482394b4d
88 sg:person.01365356361.20
89 https://www.grid.ac/institutes/grid.256304.6
90 schema:sameAs https://app.dimensions.ai/details/grant/grant.2441509
91 schema:sdDatePublished 2021-01-20T03:03
92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
93 schema:sdPublisher N252f33ef7fe84c658b328fa21a536ea8
94 schema:startDate 2008-09-12T00:00:00Z
95 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=8321603
96 sgo:license sg:explorer/license/
97 sgo:sdDataset grants
98 rdf:type schema:MonetaryGrant
99 N1b7db55a599a43019fda66c37cf9d9b6 schema:name nih_id
100 schema:value R00CA131489
101 rdf:type schema:PropertyValue
102 N252f33ef7fe84c658b328fa21a536ea8 schema:name Springer Nature - SN SciGraph project
103 rdf:type schema:Organization
104 N2c33ecbb833b4ef6ab09e10482394b4d schema:member sg:person.01365356361.20
105 schema:roleName PI
106 rdf:type schema:Role
107 N4d0199b58a1e4a20b476707b7790d0d7 schema:currency USD
108 schema:value 732057
109 rdf:type schema:MonetaryAmount
110 Nb8061ef097fa4809a8bdfa5c9145daf5 schema:name dimensions_id
111 schema:value 2441509
112 rdf:type schema:PropertyValue
113 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
114 rdf:type schema:DefinedTerm
115 sg:person.01365356361.20 schema:affiliation https://www.grid.ac/institutes/grid.256304.6
116 schema:familyName ANEJA
117 schema:givenName RITU
118 rdf:type schema:Person
119 https://www.grid.ac/institutes/grid.256304.6 schema:name GEORGIA STATE UNIVERSITY
120 rdf:type schema:Organization
121 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...